AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 258: E1-E6, 1990;
0193-1849/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamura, A.
Right arrow Articles by Abe, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, A.
Right arrow Articles by Abe, Y.

AJP - Endocrinology and Metabolism, Vol 258, Issue 1 E1-E6, Copyright © 1990 by American Physiological Society


ARTICLES

Regulation of liver angiotensinogen and kidney renin mRNA levels by angiotensin II

A. Nakamura, H. Iwao, K. Fukui, S. Kimura, T. Tamaki, S. Nakanishi and Y. Abe
Department of Pharmacology, Kagawa Medical School, Japan.

The current study was designed to evaluate the role of angiotesin II (ANG II) in the regulation of renin mRNA and angiotensinogen mRNA levels. We investigated the changes in renin mRNA levels in the kidney and angiotensinogen mRNA levels in the liver induced by ANG II infusion and by inhibition of the endogenous renin-angiotensin system with enalapril or saralasin in rats. mRNAs for angiotensinogen and renin were measured by densitometric analysis of Northern blot hybridization. After a 4-h intravenous infusion of ANG II (0.2 micrograms.kg-1.min-1), angiotensinogen mRNA level in the liver increased 2.5-fold to the control level, and renin mRNA level in the kidney decreased by 45%. Four hours after treatment with a single dose of enalapril (3 mg/kg po), angiotensinogen mRNA level in the liver decreased by 50%, and renin mRNA level in the kidney increased 1.5-fold to the control level. These mRNA levels returned to control levels 8 h after treatment. After a 4-h infusion of saralasin (2.5 micrograms.kg-1.min-1) in the low-sodium state, angiotensinogen mRNA level in the liver decreased by 45%, and renin mRNA level in the kidney increased twofold to the control level. These findings suggest that ANG II is one of the factors that regulate angiotensinogen mRNA level in the liver and renin mRNA level in the kidney.


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
C. Ingert, M. Grima, C. Coquard, M. Barthelmebs, and J.-L. Imbs
Contribution of angiotensin II internalization to intrarenal angiotensin II levels in rats
Am J Physiol Renal Physiol, November 1, 2002; 283(5): F1003 - F1010.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Kobori, L. M. Harrison-Bernard, and L. G. Navar
Enhancement of Angiotensinogen Expression in Angiotensin II-Dependent Hypertension
Hypertension, May 1, 2001; 37(5): 1329 - 1335.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. KOBORI, L. M. HARRISON-BERNARD, and L. G. NAVAR
Expression of Angiotensinogen mRNA and Protein in Angiotensin II-Dependent Hypertension
J. Am. Soc. Nephrol., March 1, 2001; 12(3): 431 - 439.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Nishimura, K. Ohtsuka, N. Iwai, H. Takahashi, and M. Yoshimura
Regulation of brain renin-angiotensin system by benzamil-blockable sodium channels
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 1999; 276(5): R1416 - R1424.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L.-X. Zou, J. D. Imig, A. M. Von Thun, A. Hymel, H. Ono, and L. G. Navar
Receptor-Mediated Intrarenal Angiotensin II Augmentation in Angiotensin II–Infused Rats
Hypertension, October 1, 1996; 28(4): 669 - 677.
[Abstract] [Full Text]


Home page
HypertensionHome page
A. R. Brasier, J. Li, and K. A. Wimbish
Tumor Necrosis Factor Activates Angiotensinogen Gene Expression by the Rel A Transactivator
Hypertension, April 1, 1996; 27(4): 1009 - 1017.
[Abstract] [Full Text]


Home page
HypertensionHome page
A. R. Brasier and J. Li
Mechanisms for Inducible Control of Angiotensinogen Gene Transcription
Hypertension, March 1, 1996; 27(3): 465 - 475.
[Abstract] [Full Text]


Home page
HypertensionHome page
L.-X. Zou, A. Hymel, J. D. Imig, and L. G. Navar
Renal Accumulation of Circulating Angiotensin II in Angiotensin II–Infused Rats
Hypertension, March 1, 1996; 27(3): 658 - 662.
[Abstract] [Full Text]


Home page
HypertensionHome page
D. Lodwick, M. A. Kaiser, J. Harris, F. Cumin, M. Vincent, and N. J. Samani
Analysis of the Role of Angiotensinogen in Spontaneous Hypertension
Hypertension, June 1, 1995; 25(6): 1245 - 1251.
[Abstract] [Full Text]


Home page
HypertensionHome page
M. R. Goldberg, T. E. Bradstreet, E. J. McWilliams, W. K. Tanaka, S. Lipert, T. D. Bjornsson, S. A. Waldman, B. Osborne, L. Pivadori, G. Lewis, et al.
Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients
Hypertension, January 1, 1995; 25(1): 37 - 46.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online